| Literature DB >> 24195770 |
Suzanne Lockyer, Rob Hodgson, Jo C Dumville1, Nicky Cullum.
Abstract
BACKGROUND: Spin in the reporting of randomized controlled trials, where authors report research in a way that potentially misrepresents results and mislead readers, has been demonstrated in the broader medical literature. We investigated spin in wound care trials with (a) no statistically significant result for the primary outcome and (b) no clearly specified primary outcome.Entities:
Mesh:
Year: 2013 PMID: 24195770 PMCID: PMC3832286 DOI: 10.1186/1745-6215-14-371
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Figure 1Review summary.
Cohort A: summary of study characteristics
| | | ||
| Not for profit | 10 | (35.7) | |
| For profit | 9 | (32.1) | |
| Mixed (not for profit and for profit) | 4 | (14.3) | |
| Not reported | 3 | (10.7) | |
| Unclear | 2 | (7.1) | |
| | | ||
| Leg ulcer | 11 | (39.3) | |
| Diabetic foot ulcer | 10 | (35.7) | |
| Pressure ulcer | 6 | (21.4) | |
| Mixed ulcers | 1 | (3.6) | |
| | | ||
| Device | 13 | (46.4) | |
| Drug | 10 | (35.7) | |
| Surgery | 3 | (10.7) | |
| Care management | 2 | (7.1) | |
| | | ||
| Placebo | 7 | (25.0) | |
| Usual care | 5 | (17.9) | |
| Device | 12 | (42.9) | |
| Drug | 2 | (7.1) | |
| Surgery | 1 | (3.6) | |
| Care management | 1 | (3.6) | |
| Weeks | 12 | [ | (3–156) |
Cohort A: prevalence and type of spin by main text by section
| | ||||||
|---|---|---|---|---|---|---|
| | ||||||
| 4 | (30.8) | 4 | (26.7) | 8 | (28.6) | |
| Focus on statistically significant results from: | | | | | | |
| Within-group analyses | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Subgroups | 4 | (30.8) | 3 | (20.0) | 7 | (25.0) |
| Secondary outcomes | 0 | (0.0) | 3 | (20.0) | 3 | (10.7) |
| Per protocol analysis | 2 | (15.4) | 1 | (6.7) | 3 | (10.7) |
| Other | 1 | (7.7) | 0 | (0.0) | 1 | (3.6) |
| 8 | (61.5) | 8 | (53.3) | 16 | (57.1) | |
| Focus on statistically significant results from: | | | | | | |
| Within-group analyses | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Subgroups | 4 | (30.8) | 4 | (26.7) | 8 | (28.6) |
| Secondary outcomes | 0 | (0.0) | 5 | (33.3) | 5 | (17.9) |
| Per protocol analysis | 2 | (15.4) | 1 | (6.7) | 3 | (10.7) |
| Claims equivalence | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Rules out adverse effect | 1 | (7.7) | 5 | (33.3) | 6 | (21.4) |
| Other | 5 | (38.5) | 0 | (0.0) | 5 | (17.9) |
| 7 | (53.8) | 10 | (66.6) | 17 | (60.7) | |
| Claims effectiveness with no acknowledgement of NS results for primary outcome | 4 | (30.8) | 4 | (26.7) | 8 | (28.6) |
| Claims equivalence | 1 | (7.7) | 5 | (33.3) | 6 | (21.4) |
| Rules out adverse effect | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Acknowledges non-significance, but emphasizes significant results for other outcomes | 3 | (23.1) | 4 | (26.7) | 7 | (25.0) |
| Acknowledges non-significance, but emphasizes treatment benefit | 2 | (15.4) | 3 | (20.0) | 5 | (17.9) |
| Emphasizes benefit based on new outcome | 1 | (7.7) | 3 | (20.0 | 4 | (14.3) |
| Other | 0 | (0.0) | 0 | (0.0) | 2 | (7.1) |
*More than one type could be used in each section of a report. NS, non-significant.
Cohort A: level of spin in abstract and main text conclusion sections
| | ||||||||
|---|---|---|---|---|---|---|---|---|
| 11 | (40.7) | 11 | (39.3) | |||||
| 4 | (14.8) | 4 | (14.3) | |||||
| 6 | (22.0) | 10 | (35.7) | |||||
| 6 | (22.0) | 3 | (10.7) | |||||
Cohort A: prevalence of spin by funding source
| | ||||
|---|---|---|---|---|
| 8 | (88.9) | 9 | (90.0) | |
| 1 | (25.0) | 2 | (50.0) | |
| 6 | (60.0) | 5 | (50.0) | |
| 1 | (25.0) | 1 | (25.0) | |
| 17 | (63.0) | 16 | (57.1) | |
Cohort B: summary of study characteristics
| | | ||
| Not for profit | 10 | (23.3) | |
| For profit | 11 | (25.6) | |
| Mixed (not for profit and for profit) | 2 | (4.7) | |
| Not reported | 20 | (45.6) | |
| Unclear | 0 | (0.0) | |
| | | ||
| Leg ulcer | 24 | (55.8) | |
| Diabetic foot ulcer | 13 | (30.2) | |
| Pressure ulcer | 5 | (11.6) | |
| Mixed ulcers | 1 | (2.3) | |
| | | ||
| Device | 28 | (65.1) | |
| Drug | 12 | (27.9) | |
| Surgery | 1 | (2.3) | |
| Care management | 2 | (4.7) | |
| | |||
| Placebo | 19 | (37.3) | |
| Usual care | 8 | (15.7) | |
| Device | 17 | (33.3) | |
| Drug | 4 | (7.8) | |
| Surgery | 2 | (3.9) | |
| Care management | 1 | (2.0) | |
| Weeks | 8 | (4–13) | 2–104 |
Cohort B: comparison between the statistical significance of results presented in the main text results section and abstract results section of reports with unclear primary outcome
| | ||||
|---|---|---|---|---|
| 100% (6) | 0% (0) | 0% (0) | 0% (0) | |
| 0% (0) | 100% (5) | 0% (0) | 0% (0) | |
| 33% (2) | 0% (0) | 50% (3) | 17% (1) | |
| 31% (8) | 39% (10) | 8% (2) | 23% (6) | |
SNS, statistically non-significant; SS statistically significant.
Cohort B: use of statistical testing to support claims of effectiveness in trial reports
| | ||||
|---|---|---|---|---|
| 32% (12) | 8% (3) | 41% (15) | 19% (7) | |
| 33% (1) | 67% (2) | 0% (0) | 0% (0) | |
| 100% (3) | 0% (0) | 0% (0) | 0% (0) | |
SNS, statistically non-significant; SS, statistically significant.